Prosecuting Insider Trading Cases is Now Even More Difficult

David Feldman  |

Supreme_Court_US_2010.jpg

Two weeks ago, the US Supreme Court said it would not hear a case in which the appeals court overturned two insider trading convictions. By refusing to hear the case, they effectively let stand the decision detailed below, which many say will make it much tougher to prosecute insider trading cases. As is the norm, the Supreme Court justices don’t say why they choose not to grant “certiorari” and hear a case.



The appeals court threw out the convictions of two hedge fund managers because the original tipping of inside information by company insiders was not proven to have been swapped for a personal benefit. The court created a very narrow definition of this benefit, and also required that the ultimate traders knew the information was originally tipped in violation of this standard, and found in this case that point was also not proven.

Not only does this get the two guys in question off, many others who have been convicted are now saying theirs should also be reversed if this is the new standard. This is also a blow for the US Attorney’s Office in NY which did a big push on insider trading in the hedge fund industry in recent years. But the law on insider trading has been murky for many years. Frankly, I’ve scratched my head at times both as to why some were convicted, while others were not. Maybe it’s time for Congress to look at setting clear standards to govern future conduct?

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…